Moreover, there are a number of in vitro or in vivo studies of cancer cell line panels that have failed to demonstrate the simple association of PIK3CA mutation or loss of PTEN expression with sensitivity to PI3K inhibitors [129,130,135-137]. This evidence concerns the gene PTEN and cancer.